Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12201977 | 1.00 | FAAH (0.32) | FAAHJAK3BTKAAK1 | |
| SCHEMBL22965941 | 0.83 | FAAH (0.33) | FAAHJAK3BTKAAK1 | |
| SCHEMBL25745260 | 0.83 | FAAH (0.33) | FAAHJAK3BTKAAK1 | |
| SCHEMBL8647813 | 0.83 | FAAH (0.33) | FAAHJAK3BTKAAK1 | |
| SCHEMBL13682813 | 0.79 | CA12 (0.38) | AAK1 | |
| SCHEMBL7020025 | 0.79 | CA12 (0.38) | AAK1 | |
| SCHEMBL23428809 | 0.79 | CA1 (0.33) | AAK1 | |
| SCHEMBL59435 | 0.79 | CA1 (0.33) | AAK1 | |
| SCHEMBL67120 | 0.79 | CA1 (0.33) | AAK1 | |
| SCHEMBL2160514 | 0.79 | CA1 (0.33) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374454-B1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI R&D MAN CO LTD (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-7772397-B2 | Biologically active peptides and compositions, their use | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772397-B2 | Biologically active peptides and compositions, their use | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20090264487-A1 | HEMIASTERLIN ANALOGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-10-22 | — | — | US | disclosed |
| US-7410951-B2 | Biologically active peptides and compositions, their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-08-12 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| EP-1531846-A4 | CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED COMPOSITIONS AND METHODS OF USE | US GOV HEALTH & HUMAN SERV (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050171014-A1 | Conjugates of ligand linker and cytotoxic agent and related composition and methods of use | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1531846-A2 | CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED COMPOSITIONS AND METHODS OF USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2003072754-A2 | CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED COMPOSITIONS AND METHODS OF USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | FAAH 3749/4885JAK3 4817/4885BTK 4435/4885 |
| US-20090264487-A1 | HEMIASTERLIN ANALOGS | NUMA1, CYP11A1, PDS5A | FAAH 3911/4885JAK3 4842/4885BTK 4849/4885 |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | FAAH 3481/4885JAK3 4844/4885BTK 4513/4885 |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | FAAH 3749/4885JAK3 4817/4885BTK 4435/4885 |
| US-20050171014-A1 | Conjugates of ligand linker and cytotoxic agent and related composition and methods of use | VCL, SELPLG, L3MBTL1 | FAAH 755/4885JAK3 4598/4885BTK 2075/4885 |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | DHCR7, CYP46A1, NR1H2 | FAAH 2554/4885JAK3 4793/4885BTK 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.